420 related articles for article (PubMed ID: 30815512)
21. CAT--the new committee for advanced therapies at the European Medicines Agency.
Celis P
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):9-13. PubMed ID: 20084354
[TBL] [Abstract][Full Text] [Related]
22. Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union.
Iglesias-Lopez C; Agustí A; Vallano A; Obach M
Front Pharmacol; 2021; 12():773712. PubMed ID: 34916948
[TBL] [Abstract][Full Text] [Related]
23. Regulatory landscape for cell therapy--EU view.
McBlane JW
Biologicals; 2015 Sep; 43(5):433-6. PubMed ID: 25997566
[TBL] [Abstract][Full Text] [Related]
24. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
25. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
[TBL] [Abstract][Full Text] [Related]
26. Advanced therapy medicinal products: current and future perspectives.
Hanna E; Rémuzat C; Auquier P; Toumi M
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
[TBL] [Abstract][Full Text] [Related]
27. [Safety monitoring of cell-based medicinal products (CBMPs)].
Funk MB; Frech M; Spranger R; Keller-Stanislawski B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
[TBL] [Abstract][Full Text] [Related]
28. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand.
Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P
Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851
[TBL] [Abstract][Full Text] [Related]
29. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
Buljovčić Z
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
[TBL] [Abstract][Full Text] [Related]
30. Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014.
Celis P; Ferry N; Hystad M; Schüßler-Lenz M; Doevendans PA; Flory E; Beuneu C; Reischl I; Salmikangas P
Transfus Med Hemother; 2015 May; 42(3):194-9. PubMed ID: 26195933
[TBL] [Abstract][Full Text] [Related]
31. European Medicines Agency's Priority Medicines Scheme at 2 Years: An Evaluation of Clinical Studies Supporting Eligible Drugs.
Neez E; Hwang TJ; Sahoo SA; Naci H
Clin Pharmacol Ther; 2020 Mar; 107(3):541-552. PubMed ID: 31591708
[TBL] [Abstract][Full Text] [Related]
32. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries.
Coppens DGM; Hoekman J; De Bruin ML; Slaper-Cortenbach ICM; Leufkens HGM; Meij P; Gardarsdottir H
Cytotherapy; 2020 Oct; 22(10):592-600. PubMed ID: 32563611
[TBL] [Abstract][Full Text] [Related]
33. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review.
Aguilera-Cobos L; Rosario-Lozano MP; Ponce-Polo A; Blasco-Amaro JA; Epstein D
Health Policy; 2022 Dec; 126(12):1248-1255. PubMed ID: 36283859
[TBL] [Abstract][Full Text] [Related]
34. Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ.
Borg JJ; Laslop A; Pani L; Maciulaitis R; Melchiorri D
Sci Pharm; 2014; 82(3):541-54. PubMed ID: 25853067
[TBL] [Abstract][Full Text] [Related]
35. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.
Ancans J
Front Immunol; 2012; 3():253. PubMed ID: 22912639
[TBL] [Abstract][Full Text] [Related]
36. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P
Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497
[TBL] [Abstract][Full Text] [Related]
37. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.
Cilia M; Ruiz S; Richardson P; Salmonson T; Serracino-Inglott A; Wirth F; Borg JJ
AAPS PharmSciTech; 2018 Feb; 19(2):489-511. PubMed ID: 29027130
[TBL] [Abstract][Full Text] [Related]
38. Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001.
Juan M; Delgado J; Calvo G; Trias E; Urbano-Ispizua Á
Hum Gene Ther; 2021 Oct; 32(19-20):1004-1007. PubMed ID: 34476985
[TBL] [Abstract][Full Text] [Related]
39. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
40. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH
Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
